IFI-M · SBK Tri-Axis Dominant-Primary Series

Specimen SS-F-M3-02779 // MULTI-AXIS · IFI-M

SBK Tri-Axis Dominant-Primary Series I-IV

Stevia rebaudiana

Stevia

Tier ISBK Tri-Axis Dominant-Primary Series

Target Trait

1.1×

fold-change

Sweet-dominant tri-axis B+K modulated fold-change

Technical Specifications

SKU

SS-F-M3-02779

Genomic Edits

6

GC Content

46.5%

Construct Length

4,118 bp

Promoter System

T7/SP6 cell-free

Expression System

In-vitro cell-free

Host Strain

Cell-free

Receptor Target

TAS1R2/TAS1R3 + TAS2R38 (suppression) + CaSR

IFI Score

110

Pathway Edits

  • TAS1R2/TAS1R3 pathway primary gene cluster for sweet (IFI-S) tri-axis component
  • TAS2R38 (suppression) pathway primary gene cluster for bitter-attenuation (IFI-B) tri-axis component
  • CaSR pathway primary gene cluster for kokumi (IFI-K) tri-axis component
  • Tri-axis metabolic flux partitioning hub for concurrent SBK pathway operation
  • Cross-pathway regulatory circuit for sweet-dominant SBK triple-axis expression
  • Cofactor regeneration system (NADPH, ATP, acetyl-CoA) supporting triple-axis concurrent production

Key Interventions

Triple-axis receptor co-activation: TAS1R2/TAS1R3, TAS2R38 (suppression), and CaSR pathways simultaneously engineeredSweet-dominant tri-axis expression strategy (SBK) with cross-pathway flux managementCell-free co-translation of multi-axis enzyme sets for in-vitro biochemical validation

IFI Subscale Profile

IFI Profile

IFI-S
—
IFI-U
—
IFI-B
—
IFI-K
—
IFI-C
—
IFI-P
—
IFI-A
—
IFI-F
—

Use Case

Tier I SBK triple-axis construct for advanced multi-modal sensory architecture combining sweet, bitter-attenuation, and kokumi axes. Suitable for ultra-premium ingredient formulation requiring certification across three simultaneous IFI receptor pathways.

License

$299 · Tier I License

Includes full construct sequence, CRISPR guide designs, pathway edit specifications, flux balance analysis, and IFI validation data.

Already purchased?